Correlation of liver enzymes and haematological profile in thalassemia major patients
Abstract
Introduction: Although red cell transfusions are lifesavers for patients with thalassemia, they are responsible for a series of complications and expose the patients to a variety of risks. Thalassemia major is the most common genetic disease caused by defective gene which produces abnormal haemoglobin.
Material and Methods: We have investigated 100 patients of Thalassemia coming to blood bank for regular blood transfusion. Level of hemoglobin,TLC,DLC and Liver enzymes i.e. SGOT, SGPT, Alkaline Phosphatase along with S. Bilirubin were also estimated. The age group of children suffering from Thalassemia major was between one year to fifteen years.
Results: Serum Ferritin Level was 2251 + 315 ng/ml(mean+S.D ), Haemoglobin level was 7.82 + 0.83 gm/dl,TLC was 7200 + 1000 cells/cmm, DLC was 68 + 12 Neutrophils,29 + 08 Lymphocytes,02 + 01 Eosinophils,01 + 00Monocytes,00 + 0.1 Basophils, SGOT (AST) value was 117 + 35.5 IU/L and SGPT(ALT) concentration 151 + 47.2 IU/L and Alkaline Phosphatase level was found to be 288 + 20.80 IU/L with mean + S.D. Bilirubin was 2.55 +1.12 mg/dl (mean + S.D).
Conclusion: In Present study Liver Enzymes increased and haemoglobin level was reduced but no changes were found in TLC and DLC.
Downloads
References
2. Mohammad reza sabri,Ahmed alavian et al, Benign extreme hyperbilirubinemia in a 9 year old girl with sickle-thalassemia and the probable role of Hb F in predicting the outcome, Medical Journal of the Islamic Republic of Iran, 1998;12(1):75-78.
3. Madan N, Sharma S, Sood SK, Colah R, Bhatia LH. Frequency of β-thalassemia trait and other hemoglobinopathies in northern and western India. Indian J Hum Genet. 2010 Jan;16(1):16-25. doi: 10.4103/0971-6866.64941.
4. Kanjaksha Ghosh et al. Guidelines for screening, diagnosis and management of hemoglobinopathies http/www/11JLG.com.3 July 2015, IP 101,59,(198-176).
5. Chetna Jain, Ajay kumar Bhargava, Narendra Mogra et al, Assessment of serum ferritin level and effects of of iron chelation, Level of Haemoglobin and Liver profile in Thalassemia major patients at tertiary care hospital in Western India ; Internatoonal Journal of basic and applied medical sciences 2015, 254-256.
6. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004 Oct;89(10):1187-93. [PubMed]
7. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012 Nov 1;120(18):3657-69. doi: 10.1182/blood-2012-05-370098. Epub 2012 Aug 23. [PubMed]
8. Cappellini MD, Cohen A, Piga A. Recent developments in iron chelation therapy. Klin .Patidar. 2007, 219(3),158-165.
9. Tietz N (Ed).Fundamentals of Clinical Chemistry ,W.S., Saunders Co. , Philadelphia PA (1986). [PubMed]
10. Cazzola M, Arosio P, Bellotti V, Bergamaschi G, Dezza L, Iacobello C, Ruggeri G, Zappone E, Albertini A, Ascari E. Immunological reactivity of serum ferritin in patients with malignancy. Tumori. 1985 Dec 31;71(6):547-54. [PubMed]
11. Yuan J, Bunyaratvej A, Fucharoen S, Fung C, Shinar E, Schrier SL. The instability of the membrane skeleton in thalassemic red blood cells. Blood. 1995 Nov 15;86(10):3945-50. [PubMed]
12. Giardina PJ, Forget BG, Hoffman R et al.Thalassemia Syndrome in Haematology basic principles and practice 5 th ed Philadelphia PA. Elsellier Churchill Livingstone 2008, 46-49. [PubMed]
13. Mills LR, Mwakyusa D, Milner PF. Histopathologic features of liver biopsy specimens in sickle cell disease. Arch Pathol Lab Med. 1988 Mar;112(3):290-4.
OAI - Open Archives Initiative
